Stay updated with breaking news from Robert Sassoon. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
In a positive step for the treatment of the rare genetic dermatological condition known as epidermolysis bullosa (EB), InMed Pharmaceuticals Inc. (NASDAQ: INM) has published top-line data from its INM-755 Phase II study.
ZeroHedge - On a long enough timeline, the survival rate for everyone drops to zero
ZeroHedge - On a long enough timeline, the survival rate for everyone drops to zero
ZeroHedge - On a long enough timeline, the survival rate for everyone drops to zero
Water Tower Research (WTR) Publishes Initiation of Coverage Report on Electrovaya Inc. (OTCMKTS: EFLVF TSX: EFL) “Powering Ahead With Lithium-Ion Bat